Novogenia AG
Research Novogenia AG (7V0.DE) on Bullrun: market cap EUR 76.80M, P/E 128.0, dividend yield 8.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7V0.DE
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 76.80M
- P/E128.0
- Dividend yield8.4%
- Financial periodFY2025
- RevenueEUR 54.30M
- Revenue growth114.7%
- Net incomeEUR 545.47K
- Free cash flow-EUR 21.65M
- Gross margin33.8%
Valuation Snapshot
latest market cap is EUR 76.80M; P/E is 128.0; dividend yield is 8.4%.
Peer valuation comparison
Latest P/E is 128x versus a Healthcare sector median of 24.61x (420.2% above).
Latest dividend yield is 8.42% versus a Healthcare sector median of 1.84% (357.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 54.30M | EUR 545.47K | -EUR 21.65M | 33.8% | 0.05 | EUR 12.53M | EUR 6.15M | EUR 100.16M |
| FY2024 | EUR 25.29M | EUR 18.46M | -EUR 29.23M | 49.0% | 1.54 | EUR 20.66M | EUR 3.22M | EUR 105.83M |
| FY2023 | EUR 18.17M | EUR 39.71K | -EUR 20.39M | 33.2% | 0 | EUR 18.45M | EUR 2.28M | EUR 93.88M |
| FY2022 | EUR 210.34M | EUR 45.07M | EUR 92.54M | 57.0% | 3.76 | EUR 90.12M | EUR 33.79K | EUR 112.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | EUR 76.80M | 128.0 | 8.8% | 0.56 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.56 EUR, yield 8.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.56 EUR |
| FY2024 | 0.56 EUR |
About Novogenia AG
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Novogenia AG's market cap?
Novogenia AG's market capitalization is EUR 76.80M.
What is Novogenia AG's P/E ratio?
Novogenia AG's price-to-earnings (P/E) ratio is 128.0.
Does Novogenia AG pay a dividend?
Novogenia AG has a dividend yield of 8.4%.
What does Novogenia AG do?
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.